Looks like deja vu

Article Excerpt

BECKMAN COULTER INC. $63 (New York symbol BEC; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 61.7 million; Market cap: $3.9 billion; WSSF Rating: Average) makes lab equipment that doctors and medical researchers use to detect substances in blood and other bodily fluids. Beckman has a long history of using acquisitions to expand its business. In 1997, the company (then called Beckman Instruments) acquired Coulter Corp. for $875 million, a world leader in blood cell analysis. Investors feared that Beckman paid too much, and the stock fell 15% on the news. But Coulter’s technology greatly expanded Beckman’s sales. The company’s latest acquisition is Biosite Inc., which makes heart disease testing equipment. The $1.55 billion price is equal to 40% of Beckman’s market cap. The high cost spooked investors, and the stock fell 8%. They also worry that Beckman is taking on too much debt; the extra borrowing will probably increase Beckman’s long-term debt, from 0.8 times equity to over 2 times. But Beckman…